Vaccines against SARS-COV-2
DOI:
https://doi.org/10.30574/gscarr.2021.8.2.0143Keywords:
Coronavirus, SARS-COV-2, Mutations, VaccinesAbstract
Vaccines against Covid-19 were developed on the basis of protein S, before it had the mutations identified in these variants. Although research conducted so far is less effective against variants and continues to offer protection against severe forms of Covid-19, further research is ongoing.
WHO is working with every country in the world to help coordinate the key stages of this vaccine manufacturing and development process. In particular, to facilitate equitable access for all countries to vaccines against Covid-19 and that they are safe and effective for the billions of people who need them.
Metrics
References
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382: 727-733.
Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015; 1282: 1-23.
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579: 270–273.
Walls et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell. 2020; 180: 1-12.
Grifoni et al. Cell Host & Microbe. 2020; 27: 671–680.
Lee CH, Koohy H. In silico identification of vaccine targets for 2019-nCoV. F1000 Research. 2020; 9: 145.
Amanat and Krammer, SARS-CoV-2 Vaccines: Status Report, Immunity. 2020.
Callaway A, Spencer N. The race for Coronavirus vaccines. Nature. 2020; 580: 576-577.
COVID-19 shot protects monkeys. Cohen. J. Science 2020; 368: 456.
Enjuanes L, et al. Molecular Basis of Coronavirus Virulence and Vaccine Development. Advances in Virus Research. 2016; 96: 245-286.
Lurie N, et al. Developing Covid-19 Vaccines at Pandemic Speed. New Eng J Med. 30 Mar 2020.
Relevant WHO documents for SARS-CoV-2 vaccines and other biologicals.
Corey L, Mascola J, Fauci AS, Collins FS. A Strategic Approach to COVID-19 Vaccine R&D. Science. 2020.
Corum J, Wee S-L, Zimmer C. Coronavirus Vaccine Tracker. The New York Times [Internet]. 2020.
Krammer F. SARS-CoV-2 vaccines in development. Nature [Internet]. octubre de. 2020; 586(7830): 516.
Draft landscape of COVID-19 candidate vaccines_3nov2020 [Internet].
Mullard A. COVID-19 vaccine development pipeline gears up. The Lancet [Internet]. 2020; 395(10239): 1751-2.
Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity [Internet]. 14 de abril de 2020; 52(4): 583-9.
Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin J-B, Olsson A, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell [Internet]. 1 2020; 183(1): 158-168.
Coronavirus: the Commission approves third contract to ensure access to a potential vaccine [Internet]. European Commission. 2020. Available in: https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines?adgroupsurvey={adgroupsurvey}&gclid=CjwKCAjw3riIBhAwEiwAzD3TiTqGDtZzRZBu6amqis5ZJMK60H0eiTv8nCsIeydheA3tweR2dMN4TRoCo-4QAvD_BwE
Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med [Internet]. 14 de octubre de. 2020.
Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine. medRxiv [Internet]. 2020.
Van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature [Internet]. 30 de julio de 2020; 1-8.
Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med [Internet]. 29 de septiembre de 2020 [citado 6 de noviembre de. 2020.
Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature [Internet]. 12 de agosto de. 2020; 1-8.
Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med [Internet]. 15 Octomber 2020; 383(16): 1544-55.
ACIP August 2020 Presentation Slides. Immunization Practices. CDC [Internet]. 2020.
Sadoff J, Gars ML, Shukarev G, Heerwegh D, Truyers C, Groot AM de, et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. medRxiv [Internet]. 25 September 2020.
Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1–2 Trial of a SARS-CoV- 2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med [Internet]. 2 September 2020.
Mercado N. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques [Internet]. Nature. 2020.
Guebre-Xabier M, Patel N, Tian J-H, Zhou B, Maciejewski S, Lam K, et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. bioRxiv [Internet]. 2020.
Bangaru S, Ozorowski G, Turner HL, Antanasijevic A, Huang D, Wang X, et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. bioRxiv [Internet]. 2020.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
